{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T06:11:11Z","timestamp":1775023871671,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.medcli.2024.03.028","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T11:30:07Z","timestamp":1717673407000},"page":"301-305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Nuevas dianas terap\u00e9uticas en hipertensi\u00f3n"],"prefix":"10.1016","volume":"163","author":[{"given":"Alejandro","family":"de la Sierra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Oliveras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2024.03.028_bib0155","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2024.03.028_bib0160","doi-asserted-by":"crossref","first-page":"109291","DOI":"10.1016\/j.steroids.2023.109291","article-title":"Molecular pharmacology of mineralocorticoid receptor antagonists: The role of co-regulators","volume":"199","author":"Koca","year":"2023","journal-title":"Steroids"},{"key":"10.1016\/j.medcli.2024.03.028_bib0165","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12882-016-0337-0","article-title":"Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis","volume":"17","author":"Currie","year":"2016","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.medcli.2024.03.028_bib0170","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.medcli.2024.03.028_bib0175","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/HJH.0000000000003330","article-title":"Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes","volume":"41","author":"Agarwal","year":"2023","journal-title":"J Hypertens"},{"key":"10.1016\/j.medcli.2024.03.028_bib0180","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","article-title":"Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN Study)","volume":"75","author":"Ito","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.medcli.2024.03.028_bib0185","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","article-title":"Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD Study","volume":"78","author":"Bakris","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.medcli.2024.03.028_bib0190","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2024.03.028_bib0195","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/jama.2023.16029","article-title":"Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the Target-HTN randomized clinical trial","volume":"330","author":"Laffin","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.medcli.2024.03.028_bib0200","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.lfs.2012.03.026","article-title":"Endothelin and endothelin receptors in the renal and cardiovascular systems","volume":"91","author":"Vignon-Zellweger","year":"2012","journal-title":"Life Sci"},{"key":"10.1016\/j.medcli.2024.03.028_bib0205","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40119-021-00233-7","article-title":"Aprocitentan, a dual endothelin receptor antagonist under development for the treatment of resistant hypertension","volume":"10","author":"Angeli","year":"2021","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.medcli.2024.03.028_bib0210","first-page":"806","article-title":"Novel dual endothelin inhibitors in the management of resistant hypertension","volume":"13","author":"Boutari","year":"2023","journal-title":"Life (Basel)"},{"key":"10.1016\/j.medcli.2024.03.028_bib0215","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(22)02034-7","article-title":"Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial","volume":"400","author":"Schlaich","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2024.03.028_bib0220","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/HYPERTENSIONAHA.119.12675","article-title":"Evolution of a new class of antihypertensive drugs: targeting the brain renin-angiotensin system","volume":"75","author":"Llorens-Cortes","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.medcli.2024.03.028_bib0225","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/CRD.0000000000000360","article-title":"Firibastat: an oral first-in-class brain aminopeptidase A inhibitor for systemic hypertension","volume":"30","author":"Khosla","year":"2022","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.medcli.2024.03.028_bib0230","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.3390\/ijms23031459","article-title":"Current knowledge about the new drug firibastat in arterial hypertension","volume":"23","author":"Hansen","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.medcli.2024.03.028_bib0235","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/HJH.0000000000001563","article-title":"Central antihypertensive effects of chronic treatment with RB150: an orally active aminopeptidase A inhibitor in deoxycorticosterone acetate-salt rats","volume":"36","author":"Marc","year":"2018","journal-title":"J Hypertens"},{"key":"10.1016\/j.medcli.2024.03.028_bib0240","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1097\/HJH.0000000000002092","article-title":"A pilot double-blind randomized placebo-controlled crossover pharmacodynamic study of the centrally active aminopeptidase A inhibitor, firibastat, in hypertension","volume":"37","author":"Azizi","year":"2019","journal-title":"J Hypertens"},{"key":"10.1016\/j.medcli.2024.03.028_bib0245","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/CIRCULATIONAHA.119.040070","article-title":"Efficacy and safety of firibastat, a first-in-class brain aminopeptidase A inhibitor, in hypertensive overweight patients of multiple ethnic origins","volume":"140","author":"Ferdinand","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.medcli.2024.03.028_bib0250","unstructured":"Firibastat fails to improve BP in resistant hypertension: FRESH [consultado 17 feb 2024]. Disponible en: https:\/\/www.healio.com\/news\/cardiology\/20221111\/firibastat-fails-to-improve-bp-in-resistant-hypertension-fresh."},{"key":"10.1016\/j.medcli.2024.03.028_bib0255","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jacc.2011.05.011","article-title":"A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community","volume":"58","author":"Cannone","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.medcli.2024.03.028_bib0260","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(00)02602-7","article-title":"Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial","volume":"356","author":"Rouleau","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2024.03.028_bib0265","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.medcli.2024.03.028_bib0270","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2024.03.028_bib0275","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1161\/HYPERTENSIONAHA.116.08556","article-title":"Effects of Sacubitril\/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension: The PARAMETER Study","volume":"69","author":"Williams","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.medcli.2024.03.028_bib0280","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1161\/HYPERTENSIONAHA.121.18114","article-title":"Endothelial natriuretic peptide receptor 1 play crucial role for acute and chronic blood pressure regulation by atrial natriuretic peptide","volume":"79","author":"Tokudome","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.medcli.2024.03.028_bib0285","unstructured":"An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients [consultado 17 Feb 2024]. Disponible en https:\/\/clinicaltrials.gov\/study\/NCT05562934?term=xxb750&rank=3."},{"key":"10.1016\/j.medcli.2024.03.028_bib0290","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2208391","article-title":"Zilebesiran, an RNA interference therapeutic agent for hypertension","volume":"389","author":"Desai","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2024.03.028_bib0295","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1001\/jama.2024.0728","article-title":"RNA interference with zilebesiran for mild to moderate hypertension: The KARDIA-1 randomized clinical trial","volume":"331","author":"Bakris","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.medcli.2024.03.028_bib0300","unstructured":"Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) [consultado 17 Feb 2024]. Disponible en https:\/\/clinicaltrials.gov\/study\/NCT05103332?term=zilebesiran&rank=1#more-information."}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775324002896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775324002896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T18:23:27Z","timestamp":1726597407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775324002896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0025775324002896"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2024.03.028","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nuevas dianas terap\u00e9uticas en hipertensi\u00f3n","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2024.03.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}